Background: Curaremimetic nondepolarizing muscle relaxants are widely used in clinical practice to prevent muscle contraction either during surgery or during intensive care. Although primarily acting at the neuromuscular junction, these compounds can cause adverse effects, including modification of cardiac rhythm, arterial blood pressure, and in the worst cases, triggering of seizures. In this study, we assessed the interaction of atracurium and its metabolite, laudanosine, with neuronal nicotinic receptors.
THE benzylisoquinoline 1 derivative atracurium (ATR) is a widely used nondepolarizing neuromuscular blocking agent, with a relatively short half-life of 20 -40 min, and a rapid elimination period. [2] [3] [4] Although well-tolerated, atracurium can cause different adverse reactions, 5, 6 such as cardiovascular effects, that are thought to be mediated by the ganglionic neuronal nicotinic acetylcholine receptor (nAChR). 7 In addition, atracurium and its degradation product laudanosine were found in cerebrospinal fluid, indicating that this compound may cross, in some circumstances, the blood-brain barrier 8, 9 and could, depending on the concentrations, affect brain function. In agreement with this hypothesis, it has been shown in animal models that, when administered at high concentration, neuromuscular blocking agents can trigger seizures. 10, 11 Furthermore, atracurium application to hippocampal slices modifies synaptic transmission. 12 The recent availability of complementary DNA (cDNA) coding for human neuronal nAChRs (reviewed in Bertrand and Changeux 13 and Lindstrom et al., 14 ) opens new possibilities for assessment of the possible effects of atracurium on these receptors. The aim of this study was to evaluate the effects of atracurium and laudanosine on the functional properties of the major brain and ganglionic human nAChRs reconstituted in Xenopus oocytes. The ␣4␤2 subunits, which are thought to constitute the major brain nicotinic receptors, were chosen as a model of central nAChRs. 13, 14 Receptors corresponding to those found in ganglia were obtained by expression of ␣3␤4 or ␣3␤4␣5 subunits. 15 In addition, we evaluated atracurium and laudanosine effects on the homomeric ␣7 nAChR that is expressed centrally and peripherally. 13,16 -18 Methods Oocyte Preparation and cDNA Injection Xenopus oocytes were isolated and prepared as previously described. 19 Oocytes were intranuclearly injected with 2 ng cDNA. All subunits were injected with an equal concentration. Oocytes were kept separately in a 96-well microtiter plate (NUNC) at 18°C in Barth solution (88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO 3 , 10 mM HEPES, 0.82 mM MgSO 4 7H 2 O, 0.33 mM Ca(NO 3 ) 2 .4H 2 O, 0.41 mM CaCl 2 .6H 2 O, at pH 7.4 adjusted with NaOH, and supplemented with 20 g/ml kanamycine, 100 U/ml penicillin, and 100 g/ml streptomycine). Atracurium (Tracrium ® ) was purchased from Glaxo Wellcome (London, UK). All other drugs, including ACh, laudanosine and atropine were purchased from Sigma (Buchs, Switzerland).
Electrophysiology
Current recordings from oocytes were performed at 18°C, 2-4 days after cDNA injections. During the recording, cells were continuously superfused with original Ringer 2 (82.5 mM NaCl, 2.5 mM KCl, 5 mM HEPES, pH 7.4 adjusted with NaOH) with either Ca 2ϩ or Ba 2ϩ (2.5 mM). All drugs were diluted in an original Ringer 2 medium The flow rate was approximately 6 ml/min and the volume chamber was less than 100 l. To prevent possible activation of endogenous muscarinic receptors, 0.5 M atropine was added. Electrophysiologic recordings were performed with a two-electrode voltage clamp (GENECLAMP amplifier; Axon Instruments, Forster City, CA). Electrodes made from 1.2 mm borosilicate Q tubes were pulled using a BB CH PC puller (Mecanex, Nyon, Switzerland), and filled with 3 M KCl. Unless specified, cells were clamped at a holding potential of Ϫ100 mV and the current was measured at the peak current. All experiments were performed at 18°C. Current-voltage relations were determined by a linear voltage ramp. To best show open channel blockade, cells were first briefly held at ϩ40 mV and the voltage was then ramped down within 500 ms to 100 mV. Current-voltage relation curves were obtained by reporting the current values measured every 4 mV. Subtraction of the currents determined in control conditions from those measured during ACh exposure allowed determination of the nAChR current-voltage relations in isolation.
Data Analysis
Concentration-response curves were adjusted using the empirical Hill equations;
where Y is the fraction of activated current, EC 50 is concentration of half-activation, nH is the apparent cooperativity, and x is agonist concentration.
where Y is the fraction of remaining current, IC 50 is concentration of half-inhibition, nH is the apparent cooperativity, and x is antagonist concentration. Values indicated throughout the text are given with their respective standard deviations (SD).
Results
Evidence, including results obtained from biochemical and electrophysiologic studies, has shown that d-tubocurarine produces multiple effects at the neuromuscular nAChR junction. Effects caused by this molecule are (1) competitive inhibition, 20, 21 (2) open channel blockade, 22, 23 and (3) direct activation of the receptor. 24 -26 Therefore, when evaluating possible effects of the structurally related atracurium molecule on neuronal nAChRs, it is necessary to distinguish among these three modes of action.
Effects of atracurium on the Central or Ganglionic nAChRs
To determine atracurium effects in steady state conditions, this compound was pre-and coapplied with ACh.
As shown in figure 1A , the application of 10 M atracurium markedly inhibits the ACh-evoked current at the ␣4␤2 nAChR. This effect was reversible within 1 min of washout. A comparable inhibition of ACh-evoked current was observed at 4 M atracurium for the ganglionic ␣3␤4 and ␣3␤4␣5 nAChRs and at 10 M atracurium for the ␣7 receptor. Full recovery was observed within 2 min. For each of these receptor subtypes, the ACh concentration test pulse was adjusted to near their respective EC 50 . A small inward deflection of the current was observed during atracurium application alone on the ␣4␤2 and ␣3␤4 receptors. To evaluate further this putative receptor activation, currents evoked by low ACh concentrations were compared with those evoked by either atracurium or laudanosine alone ( fig. 1B ). Increasing the drug concentrations greater than those shown always resulted in a smaller current, indicating that these compounds act as inhibitors at relatively higher concentrations. The comparison of the currents evoked by ACh, atracurium, and laudanosine on a log-log scale, highlights the differences in sensitivity of the ␣4␤2 and ␣3␤4 receptors to these three substances, with ACh always being the most effective agonist.
As shown in figure 1B , data are well-fitted by straight lines and yielded respective slope values of 0.73 and 0.78 for ACh and atracurium on the ␣4␤2 and 1.22, 0.6, and 0.31 for ACh, laudanosine, and atracurium on the ␣3␤4. Offset values were 2.72 and 2.3 for ACh and atracurium on the ␣4␤2 and 1.5, 0.56, and Ϫ0.02 for ACh, laudanosine, and atracurium on the ␣3␤4. All correlation factors were superior to 0.95. As expected for a receptor with a lower affinity, all responses on the ␣3␤4 are shifted to the right. Therefore, the relative agonist sensitivities are ACh greater than atracurium on ␣4␤2 receptors and ACh greater than laudanosine greater than atracurium on ␣3␤4 receptors. Laudanosine alone, however, evoked no detectable current at ␣4␤2. Similarly, no currents could be recorded in response to atracurium or laudanosine exposure at the homomeric ␣7 receptors (data not shown). Given the paucity of ␣5 expression and the absence of distinguishable atracurium effects, no attempts were made to characterize the activation of this receptor subtype.
Dual Blockade Mechanisms of Atracurium
To further characterize the atracurium inhibition, we first evaluated the atracurium concentration-response inhibition curve at a fixed ACh test condition ( fig. 2 and table 1). Afterward, atracurium was kept at a constant concentration while the concentration of ACh was progressively increased. As shown in figure 2A , IC 50 of the ␣4␤2 nAChR was observed at 1.5 M atracurium, for 0.1 M ACh test pulse. Increasing the ACh concentration decreased the IC 50 value, suggesting that atracurium and ACh may compete for the same binding site at ␣4␤2. The competitive nature of atracurium blockade at the ␣4␤2 nAChR was further confirmed with the evaluation of how atracurium altered the ACh concentration-response relation ( fig. 2B ). For each cell, data were normalized to the saturating current recorded at maximal ACh concentration (1 mM) in control conditions. The graph shows that 10 M atracurium caused a shift of the concentration-response curve toward higher concentrations (table 1) , without affecting the maximal evoked current.
As shown in figures 2C and 2D, a different pattern of inhibition was observed at the ganglionic ␣3␤4 receptor. First, inhibition was independent of the ACh concentra-tion ( fig. 2C ). Second, atracurium caused only a small decrease on the ACh sensitivity, and blockade could not be relieved by increasing the ACh concentration. Because it is known that ␣5 receptor contributes to a fraction of ganglionic receptors, 15 the effects of atracurium were assessed after coinjection of ␣3, ␤4, and ␣5 subunits. As shown in table 1, injection of this subunit caused no detectable changes in atracurium affinity. No differences could be observed on the ACh concentration-response profile either (data not shown). These results suggest that atracurium may act on the ganglionic receptor as an open channel blocker. Quantification of the atracurium inhibition at the ␣7 receptor with three ACh test pulse conditions indicates that, as for the ␣4␤2 nAChR, the IC 50 progressively shifted toward the lower sensitivities as the agonist concentration was increased ( fig. 2E, table 1 ). The IC 50 dependency of the ACh concentration is indicative of the competitive mode of action of atracurium. This hypothesis was further reinforced by the observation that atracurium inhibition is fully overcome by an increase of the ACh concentration ( fig. 2F ). Because ␣7 is highly permeable to Ca 2ϩ (its response may be contaminated by calcium-dependent chloride activation), atracurium concentration-response inhibitions were measured in a Ba 2ϩ -containing medium, a condition that is known to reduce chloride activation. 27 Substitution of extracellular calcium by barium caused a small shift to the left of the IC 50 and slightly increased the EC 50 (300 -430 M, data not show). This indicates that, even when present, chloride contamination plays a minor role in the atracurium blockade. The lower calcium permeability of ␣4␤2 or ␣3␤4 receptors would imply that calcium-dependent chloride contamination might also be neglected for these subtypes. Therefore, all further experiments were performed during normal divalent cation conditions.
Effects of Laudanosine on the Central or Ganglionic nAChRs
To isolate the effects of atracurium from those of laudanosine, experiments were performed using pure laudanosine. When the same experimental protocols as those presented in figure 2 were used, we found that laudanosine also inhibits the ␣4␤2, ␣3␤4, and ␣7 receptors ( fig. 3, table 2) .
Measurement of the fraction of ACh current inhibition at ␣4␤2 as a function of agonist concentration showed that laudanosine blockade was only partially removed by increasing the ACh concentration ( fig. 3A) . As for atracurium, adequate curve fitting was obtained with the Hill equations (equation 1), providing addition of a scaling factor of 0.65 to account for the laudanosine insurmountable blockade. These data show that, in contrast to atracurium, the mechanism of laudanosine blockade on the ␣4␤2 receptor is competitive, but this compound acts also in a noncompetitive manner for at least 35% of the blockade. Typical ACh-evoked currents recorded in control and during coapplication of laudanosine, are shown in figure (table 2) . Here we used low ACh concentration to avoid rapid desensitization of this receptor.
A difference in the mode of action between atracurium and laudanosine was also identified at the ganglionic ␣3␤4 nAChR (figs. 3C and D). Figure 3C shows the dual mode of blockade caused by laudanosine with a shift in the ACh EC 50 (table 2) (table 2) .
A dual mode of action of laudanosine was also observed on the ␣7 receptor but with a smaller fraction of insurmountable blockade (fig. 3E ). The Hill equation 1 was used with a scaling factor of 0.85, introduced into the curve fitting to account for this small fraction of blockade. The ACh EC 50 increased from 80 to 240 M during exposure to 30 M laudanosine (table 2) . It is well-documented that when charged molecules enter and block the ionic pores of a ligand-gated channel, its fraction of blockade will depend on the transmembrane potential. 28,29 Therefore, if laudanosine causes a blockade by steric hindrance in the channel pore, its inhibition may be voltage dependent. Typical current-voltage relations recorded in control and during laudanosine exposure showed a marked voltage dependency of laudanosine blockade (fig. 3F ). The small rebound observed at the end of the ACh-laudanosine application is coherent with a mechanism of open channel blockade. Determination of the concentration-response inhibition profile with an ACh test pulse of a 100 M yielded an IC 50 of 18.3 M (table 2).
Discussion
Recent advances in molecular biology and DNA cloning have identified the nAChR subtypes expressed in various regions of the central and peripheral nervous system (reviewed in Bertrand and Changeux 13 and Lindstrom et al. 14 ) . Central nicotinic receptors mainly con- tain the ␣4 and ␤2 subunits, whereas ganglionic receptors result from the assembly of ␣3 and ␤4.
Coimmunoprecipitation experiments have shown that a fraction of ganglionic receptors also contain the ␣5 subunit. 15 Finally, it has been shown that the homomeric ␣7 receptor is expressed centrally and peripherally. To evaluate the possible interaction between neuronal nAChRs and atracurium and its first degradation product laudanosine, these two substances were applied alone or with ACh on Xenopus oocytes expressing the human ␣4␤2, ␣3␤4, ␣3␤4␣5, and ␣7 receptors. Incubation with atracurium or laudanosine caused a marked inhibition of these four receptor subtypes, with IC 50 s in the micromolar range (tables 1 and 2). Blockade of the ACh-evoked current was fast, and complete recovery was obtained within 1 min, indicating rapid onset and offset kinetics. In addition, as expected from data obtained on muscle nAChRs, atracurium and laudanosine effects are multiple: (1) competitive inhibition, (2) open channel blockade, and (3) activation of the receptor. The latter effect was observed only for the central ␣4␤2 and ganglionic ␣3␤4 receptors. It is noteworthy to recall that the ␣5 subunit does not contribute to the pharmacologic profile of the ganglionic receptor. 30 Therefore, it is not surprising that injection of this subunit caused no detectable changes in atracurium sensitivity of the ␣3␤4 receptor.
One of the difficulties in the study of the effects caused by atracurium is the instability of this product. It is well-documented that one molecule of atracurium quickly degrades into two laudanosine molecules. The Hoffman degradation of atracurium is independent of biologic processes and therefore precludes an evaluation of the effects of atracurium alone. A few percent contamination of laudanosine in the atracurium solution cannot be excluded. A comparison of the atracurium and laudanosine effects is mandatory to understand their respective contribution. As shown in figures 2 and 3, where atracurium and laudanosine caused a comparable inhibition, a marked difference between these two compounds was observed when comparing the fraction of current they can activate. The major brain ␣4␤2 nAChR was activated by low atracurium concentrations but was unresponsive to laudanosine (data not shown). In contrast, the ganglionic ␣3␤4 nAChR was activated by laudanosine but almost unresponsive to atracurium. Plots of the ACh, atracurium, and laudanosine currents evoked by low concentrations of these three compounds on a log-log scale show that neuronal nAChRs are at least five to fifty times more sensitive to ACh than to curaremimetics. At higher concentrations, atracurium and laudanosine inhibit the ACh-evoked currents. In the absence of significant differences between the ␣3␤4 and the ␣3␤4␣5 receptor profiles and given the paucity of expression of these latter receptor subtypes, activation experiments were therefore not performed.
Plasma levels of atracurium range between 0.5 and 5.1 g/ml (0.4 and 4.1 M, respectively), with the lowest values found during surgical anaesthesia and the highest during intensive care conditions. The degradation of one atracurium molecule into two laudanosine molecules implies that a plasma concentration as high as 8 M can be reached for the latter compound. Considering these data, it was important to determine whether these compounds can be responsible for adverse effects by direct action on neuronal nicotinic receptors.
The major central nicotinic receptor ␣4␤2 was blocked by atracurium and laudanosine with an IC 50 of 1.4 and 9.4 M, respectively, when stimulated with 0.1 M ACh (tables 1 and 2). The ACh EC 50 was shifted toward higher concentration in the presence of a constant atracurium concentration (figs. 2B and 3B). The atracurium blockade was fully reversible by increasing the ACh concentration, whereas an insurmountable block of approximately 35% persisted with laudanosine. This indicates differences in the mode of action, with these two compounds atracurium inducing a purely competitive blockade and laudanosine a mixed competitive and noncompetitive action. These data are in agreement with previous findings that showed that d-tubocurarine, a related chemical structure, is a competitive inhibitor on the chick ␣4␤2 nAChR with an IC 50 in the micromolar range. 31 Evidence for open channel blockade is clearly seen with the rebounds observed at the end of ACh and laudanosine coapplication on the ␣4␤2 receptor ( fig. 3B) . The difference observed in EC 50 for the ␣4␤2 receptor between tables 1 and 2 is attributable to the use of different oocyte batches. A recent report showed that the neuronal nAChR concentration-response curves are best fitted using the two Hill equations. 32 However, because of technical limitations, the number of points collected was restricted and does not allow for further conclusion.
Muscle relaxant drugs have been described to have adverse effects and, in the worst cases, can trigger seizures in vitro or in the animal model. 10, 11 Here we report that atracurium and laudanosine can block the major brain nicotinic receptor at concentrations that can be present in the plasma of patients. Recently mutations on the ␣4 subunit have been shown to induce autosomal dominant nocturnal epilepsy (reviewed in Steinlein 33 ). It follows that a modification of the ␣4␤2 receptor activity could be the origin of seizures. Even if these receptors are exclusively expressed in the brain and thus protected by the blood-brain barrier, it has been already shown that atracurium and laudanosine can be found in cerebrospinal fluid. 8, 9 This suggests that part of atracurium adverse effects may be caused through its action on the ␣4␤2 receptor.
A different mode of action was observed at the ganglionic ␣3␤4 nAChR with atracurium and laudanosine, causing a noncompetitive blockade. Note that, in agreement with the absence of effects of ␣5 on ganglionic receptor pharmacology, the addition of ␣5 caused no 34 Recalling that the blood-brain barrier does not isolate autonomic ganglia, it is conceivable that concentrations of atracurium and laudanosine comparable with plasma levels may be reached in their environment. Our data are in agreement with previous hypotheses that adverse cardiovascular effects may be attributed to the direct action of atracurium or laudanosine on cardiac ganglia. 7 At the homomeric ␣7 receptor, atracurium acts as a competitive inhibitor. This was shown by the shift in the IC 50 of the atracurium blockade in function of the ACh test pulse concentration and by the full relief of inhibition observed at saturating ACh. Therefore, as for the ␣4␤2 and ␣3␤4, it can be concluded that the effects caused by laudanosine contaminant on ␣7 are negligible. Previous studies of the blockade caused by d-tubocurarine have shown that this compound acts as a noncompetitive blocker on the chick receptor and that 0.5 M was already sufficient to reduce by 40% the ACh evoked current. 35 Although initially different, these results and ours are not contradictory. The difference in the mode of action between atracurium and d-tubocurarine may be attributed to the difference in size between these two molecules. Moreover, experiments performed with the desensitized open L247T receptor have shown the dual mode of action of d-tubocurarine, with activation and blockade of this mutant. 36 Although it was proposed that, in some cases, perfusion conditions might affect the ␣7 responses in Xenopus oocytes, 37 we think that the agreement between our results and those obtained with the same cDNA expressed in human embryonic kidney cells is indicative of adequate experimental conditions. Therefore, no attempts were made to compensate ACh concentration-response curves, and raw data are presented herein.
The ␣7 receptor is expressed in both the central and the peripheral nervous systems (reviewed in Bertrand and Changeux 13 and Lindstrom et al. 14 ) , but also in nonneuronal cells such as the embryonic skeletal muscle cells. However, ␣7 has never been found in adult innervated muscle. 38 -40 According to these findings, we can conclude that muscular effect observed during atracurium treatment cannot be caused by interaction with ␣7 receptors. The atracurium and laudanosine IC 50 values on this receptor were 3.1 and 18.3 M, respectively. These data confirmed that atracurium and laudanosine in therapeutic conditions could block ␣7 receptors. Therefore, we cannot exclude that side effects observed during atracurium administration could be caused by a direct effect on these receptors.
In conclusion, we have shown that atracurium and laudanosine interact with neuronal nicotinic ACh receptors at concentrations that can be present in clinical conditions.
